Veritable’s Haemonetics HAE Stock Holding History

Veritable’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-8,879	Closed	-$367K	–	947
2013 Q2	$367K	Buy	+8,879	New	+$359K	0.01%	662

Other funds holding HAE

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Veritable's HAE Position: Q3 2013 in Review

Veritable sold out of Haemonetics (HAE) in Q3 2013, closing a stake of 8,879 shares — an estimated $367K sold.

Veritable first reported a position in HAE in Q2 2013 and held it in 1 quarter. The position peaked at $367K in Q2 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q3 2013.

Veritable reported no remaining Haemonetics position as of Q3 2013 after selling out during the quarter.
Veritable sold 8,879 Haemonetics shares in Q3 2013, an estimated $367K.
Veritable first reported a position in Haemonetics in Q2 2013 and held it in 1 quarter.
Veritable's Haemonetics position peaked at $367K in Q2 2013.
192 funds tracked by Wall St. Rank held Haemonetics as of Q3 2013.

Based on Veritable's 13F filing for Q3 2013, filed 13 Nov 2013.